In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled with the discovered monotherapy dosign regimen. In Segment B, individuals will obtain oral ruxolitinib and ABBV-744 are going to be provided as "insert-on" therapy. In https://hesiodm990lvj6.wikiitemization.com/user